The study on AOD9604, a peptide derivative of human growth hormone (hGH), highlights its development as a potential anti-obesity treatment. AOD9604 is derived from the hGH fragment 177–191, known for its ability to increase lipolysis (fat breakdown) and decrease lipogenesis (fat storage) without impacting growth hormone-related functions like bone growth.
Key findings include:
-
Enhanced Bioactivity: AOD9604 demonstrated a 52.4% increase in biological activity compared to its parent peptide in vitro.
-
Weight Management: Chronic treatment with AOD9604 in obese mice reduced body weight gain and total body triglycerides significantly.
-
Safety Profile: Unlike full-length hGH, AOD9604 did not affect bone growth or tibia length, emphasizing its specificity and safety.
The research concludes that AOD9604 is a promising candidate for human weight management due to its targeted action and lack of adverse effects. Early human trials showed favorable outcomes, paving the way for its use as a therapeutic peptide in combating obesity and optimizing metabolic health.
Leave a Reply